Spondyloarthritis & psoriatic arthritis
Retention rate and predictors of discontinuation for secukinumab treatment: real-life data in a cohort of patients with spondyloarthritis
Authors' conclusion
Secukinumab demonstrates sustained effectiveness in SpA patients, with a significant proportion maintaining therapy over time. Retention is influenced by BMI, prior treatments, and disease phenotype
Study context
- Population
- Patients with spondyloarthritis (SpA) treated with secukinumab at a referral centre64.6% female
- Participants
- 178 patients
- Outcome
- Secukinumab drug retention rate (time-to-discontinuation) and baseline predictors of discontinuation
- Follow-up
- 12 months and end of study
Methodological detailsobservational, single referral centre, Cox proportional hazards regression
- Observational
- Single referral centre
- Cox proportional hazards regression
Main finding
As reported in the abstract
Drug retention rate
| Group | Value | Overall drug retention rate (DRR) | Retention at 1 year |
|---|---|---|---|
| Secukinumab | 64% | 64% | 78% |
Secukinumab
Value64%
Overall drug retention rate (DRR)64%
Retention at 1 year78%
Observational data: associations, not effects.
Further findings
Predictors of long-term discontinuation · end of study
| HR (95% CI) | P value | ||
|---|---|---|---|
| Higher BMI | 1.07 (1.02–1.12) | P = 0.010 | |
| Previous treatments | 1.34 (1.03–1.73) | P = 0.030 | |
| 0.512Hazard ratio (log scale) |
Predictors of 12-month discontinuation
| HR (95% CI) | P value | ||
|---|---|---|---|
| Peripheral phenotype | 4.28 (1.26–14.48) | P = 0.019 | |
| Prior biologic/targeted synthetic therapies | 1.76 (1.24–2.51) | P = 0.002 | |
| Axial involvementProtective | 0.37 (0.17–0.83) | P = 0.016 | |
| 0.050.21520Hazard ratio (log scale) |
Reasons for discontinuation
- Secondary inefficacy
- 57.8%
- Primary inefficacy
- 25%
Safety
Discontinuation due to adverse events (proportion of discontinuations)
- Adverse events as discontinuation reason
- 17.2%
- Infections the most common adverse event
Original publication
Retention rate and predictors of discontinuation for secukinumab treatment: real-life data in a cohort of patients with spondyloarthritis. Clin Exp Rheumatol. Published 14 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →